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SUMMARY
DNA methylation serves as a major epigenetic modification crucial to the normal or-
ganismal development and the onset and progression of complex diseases such as cancer.
Computational predictions for DNA methylation profiling serve multiple purposes. First,
accurate predictions can contribute valuable information for speeding up genome-wide DNA
methylation profiling so that experimental resources can be focused on a few selected while
computational procedures are applied to the bulk of the genome. Second, computational
predictions can extract functional features and construct useful models of DNA methyla-
tion based on existing data, and can therefore be used as an initial step toward quantitative
identification of critical factors or pathways controlling DNA methylation patterns. Third,
computational prediction of DNA methylation can provide benchmark data to calibrate
DNA methylation profiling equipment and to consolidate profiling results from different
equipments or techniques.
This thesis is written based on our study on the computational analysis of the DNA
methylation patterns of the human genome. Particularly, we have established computational
models (1) to predict the methylation patterns of the CpG islands in normal conditions,
and (2) to detect the CpG islands that are unmethylated in normal conditions but aber-
rantly methylated in cancer conditions. When evaluated using the CD4 lymphocyte data
of Human Epigenome Project (HEP) data set based on bisulfite sequencing, our computa-
tional models for predicting the methylation status of CpG islands in the normal conditions
can achieve a high accuracy of 93-94%, specificity of 94%, and sensitivity of 92-93%. And,
when evaluated using the aberrant methylation data from the MethCancerDB database for
aberrantly methylated genes in cancer, our models for detecting the CpG islands that are
unmethylated in normal conditions but aberrantly methylated in colon or prostate cancer
can achieve an accuracy of 92-93%, specificity of 98-99%, and sensitivity of 92-93%.
x
The contribution of this thesis lies in three aspects. First, we identify various genetic
and epigenetic features that are associated with the methylation status and cancer related
aberrant methylation of the CpG islands in human chromosomes. These features provide the
foundation for exploring the exact mechanisms of DNA methylation in normal organismal
development and cancerogenesis. Second, our DNA methylation predictive model serves as
a fast and effective way to explore genome-wide CpG island methylation profiles in normal
tissues. Third, our predictive model for cancer related aberrant methylation can be used as




Epigenetics refers to a somatically inheritable pattern of gene expression that is determined
by mechanisms other than those encoded in DNA sequences. DNA methylation is an im-
portant type of epigenetic modification, implicated in critical cellular functions including
genetic imprinting, X-chromosome inactivation, suppression of retroviral elements, and car-
cinogenesis. In mammals, DNA methylation involves the addition of a methyl group to
DNA via DNA methyltransferase (DNMT), and typically occurs at the cytosine residues in
a CpG dinucleotide context [1][2].
CpG dinucleotides in human genome are relatively rare but are enriched in short DNA
segments known as CpG islands (CGIs) [3]. Most CpG dinucleotides are methylated in
human somatic cells [4], but the CpG dinucleotides residing within CGIs tend to remain
unmethylated. A CGI is traditionally defined as a stretch of DNA sequence that fulfills the
Gardiner-Garden criteria: (i) with ≥200 base pairs (bps), (ii) with a GC content >50%, and
(iii) with an observed/expected CpG ratio ≥60% [5]. CGIs often colocalize with functional
promoter regions, and the methylation status of CGI serves as an important mechanism
for epigenetic gene control. In human genome, CGIs overlap with the promoter regions of
approximately 50-60% of known genes, including most housekeeping genes [6].
On the one hand, DNA methylation can be determined experimentally using biochemical
experiment-based approaches. On the other hand, computational modeling can effectively
complement the wet chemistry approach to identify critical features or pathways control-
ling DNA methylation patterns, to provide valuable information when the DNA methylation
data are unavailable for certain genomic regions, as well as to calibrate DNA methylation
profiling equipment and to consolidate profiling results from different equipments or tech-
niques.
We perform computational analysis of the DNA methylation and aberrant methylation
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patterns in human genome. The objective of this work is to (a) identify various features
that are associated with the methylation status of CGIs in normal tissues and aberrant
methylation of CGIs in cancerous conditions, (b) discriminate between CGIs that are prone
to methylation from those that are resistant to methylation based on the identified features,
and (c) distinguish the aberrantly methylated CGIs in cancer from those that are consis-
tently unmethylated.
The outline of the remaining document is as follows.
Chapter II introduces the biological background of DNA methylation, followed by a
brief review of biochemical experiment-based DNA methylation profiling techniques, and
summary of major existing DNA methylation data sets and databases. Then, computational
modeling for DNA methylation and our contributions are introduced.
Chapter III presents a schematic overview of the workflow designed for predicting methy-
lation status of CGIs in normal tissues, and detecting cancer related aberrant methylation
in our research.
Chapter IV introduces how we incorporate various resources to form the training data
for CGI methylation prediction in normal tissues, and the training data for cancer related
aberrant methylation prediction.
Chapter V presents details of our method developed and implemented for predicting CGI
methylation and cancer related aberrant methylation. The model development consists of
three core parts – feature extraction, feature selection and model construction through
prediction tests.
Chapter VI provides the results and discussions of our experiments, including (i) various
genetic and epigenetic features that have been identified to be associated with the methy-
lation status of the CGIs in normal tissues and CGI aberrant methylation in cancer, (ii)
performance of our predictive models for CGI methylation in normal tissues, and (iii) per-
formance of our predictive model to detect potential CGIs that are aberrantly methylated
in cancer.
2
Chapter VII draws conclusions and discusses possible future directions for DNA methy-
lation.
Chapter VIII includes the appendices for the supplementary materials, including the
abbreviated terms used in this thesis and the results of enrichment analysis.
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CHAPTER II
ORIGIN AND HISTORY OF THE PROBLEM
2.1 Biological Background
Epigenetics is the study of heritable changes in genotypes or phenotypes caused by mech-
anisms that are not encoded in the underlying DNA sequence [7]. DNA methylation is
a type of epigenetic modification which involves the addition of a methyl group to DNA
via DNMT. In mammals, DNA methylation typically occurs at the cytosine residues in a
CpG dinucleotide context (i.e., a cytosine directly followed by a guanine) [1]. The “p” in
a CpG dinucleotide denotes the phosphodiester bond between the cytosine and the gua-
nine residues. Generally, CpG dinucleotides are observed to be relatively rare in most se-
quenced mammalian genomes (observed/expected CpG ratio: ∼20%-25%), which is mainly
attributed to the hypermutability of methylated CpG to TpG or CpA in the complementary
strand [8]. However, CpG dinucleotides are enriched in short DNA segments known as CpG
islands (CGIs), as compared to bulk DNA [9].
Traditionally, a CGI is defined as a sequence region that fulfills the Gardiner-Garden
criteria: (i) at least 200 base pairs (bps), (ii) with a GC content that is greater than 50%, and
(iii) with an observed/expected CpG ratio that is greater than 60% [5]. CGIs are generally
located around the 5’ end of genes and considered as gene markers [10]. Most (70-80%) of
the CpG dinucleotides are generally methylated in human somatic cells [4]. However, unlike
the global methylation of CpGs in the bulk of the genome, the CpG dinucleotides residing
within CGIs tend to be unmethylated.
DNA methylation plays an important role for gene control during normal cell develop-
ment and cell differentiation. For example, it has been demonstrated that DNA methyla-
tion, together with DNMT1 (one type of DNMT), is instrumental to the regulation of gene
expression in T cells during the cell development stage [11]. And, in differentiated cells,
genes encoding pluripotency transcription factors are suppressed by DNA methylation so
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as to avoid de-differentiation [12][13]. DNA methylation is also associated with a number of
key processes including genomic imprinting [14], X-chromosome inactivation in females [15],
maintenance of repetitive elements [16], and tumorigenesis [17]. For example, hypermethy-
lation of tumor suppressor genes (TSGs) and hypomethylation of oncogenes are associated
with various cancers, including sporadic retinoblastoma [18], prostate cancer [19], liver can-
cer [20] and salivary gland adenoid cystic carcinoma [21]. Numerous studies have suggested
that DNA methylation patterns can be used for early detection and precise sub-typing of
cancers, and to predict and monitor drug/therapeutic effects [22, 6, 23].
As a result, it is helpful to study the different methylation patterns of CGIs around
certain key genomic regions (e.g. cancer-related genes) compared with other genomic re-
gions (e.g. constitutively unmethylated regions). However, all these studies of differential
methylation are very much impeded by the lack of genome-wide and tissue-specific CGI
methylation data. Due to the above reasons, the profiling and prediction of DNA methyla-
tion status of CGIs in human genomes has become one of the most pressing and important
topics in computational biology recently.
2.2 Biochemical Experiment-based DNA Methylation Profiling
The biochemical experiment-based approaches for characterizing DNA methylation are
mainly based on bisulfite conversion, methylation-specific restriction and immunoprecip-
itation, respectively [24]. These approaches are usually accompanied by array-based or
high-throughput sequencing-based DNA methylation analysis. We here briefly describe
these approaches [25].
Bisulfite conversion: When the DNA is treated with sodium bisulfite, the unmethy-
lated cytosines are converted to uracils and then to thymines during polymerase chain
reaction (PCR) amplifications, while the methylated cytosines remain unchanged [26]. The
bisulfite treated DNA can then be interrogated by array hybridization (e.g., high density
tiling array-based genome-wide DNA methylation profiling [27]) or DNA sequencing to
determine which CpG dinucleotides are methylated. Particularly, with the advance of se-
quencing techniques (e.g., Illumina sequencing [28][29], Roche 454 pyrosequencing [30] and
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ABI SOLiD sequencing [31]), bisulfite sequencing has gained its popularity and is becom-
ing the gold standard in detecting DNA methylation [32][33]. Basically, regions of interest
are amplified and cloned, then clones are sequenced to confirm methylation (presence of
cytosine) or no methylation (presence of thymine at a known CpG). Because the bisul-
fite treatment introduces changes to the DNA sequence that depend on the methylation
status of individual cytosine residues, this approach can potentially yield single-nucleotide
resolution information about the methylation status of the DNA.
Methylation specific restriction enzyme digestion: The biochemical foundation
of this approach is that some restriction enzymes (methylation dependent restriction en-
zymes, MDREs) are able to, while some other restriction enzymes (methylation sensitive
restriction enzymes, MSREs) are unable to cleave methylated cytosines in their recognition
sites. For instance, HpaII, a commonly used MSRE, recognizes CCGG and is unable to cut
DNA when the internal cytosine is methylated [34]. McrBC, a commonly used MDRE, rec-
ognizes two half sites of the form (G/A)mC and does not act upon unmethylated DNA [35].
The Restriction Enzyme Database (REBASE) contains a more complete list and detailed
information of MDREs and MSREs [36]. After DNA digestion using MDREs or MSREs,
further processing is needed to derive the DNA methylation information. The first way
of deriving the DNA methylation information is based on the distribution of the length of
the digested fragments – methylated DNA that cannot be digested tend to result in longer
fragments [37]. The second way is based on real time quantitative PCR (qPCR) with spe-
cially designed primers. For example, by using the primers that are specifically designed to
target hypermethylated DNA fragments, Ng, et al., were able to calculate the difference be-
tween the cycle threshold values of the methylated and unmethylated fragments and then
estimate the percentage of methylation [38]. Real-time qPCR has gained its popularity
for quantifying the methylation status recently [39][40]. Most recently, Ng, et al., devel-
oped a MSRE-based quantitative assay to measure percentage of methylation in plasma
[38]. No matter digested or not by restriction enzyme, the remaining DNA was quantified
by qPCR using primers flanking the hypermethylated promoter CpG region. Percentage
of methylation in tissue samples was calculated by the difference of the cycle threshold
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(Ct) values from methylated signal and Ct values from unmethylated signal formulated as:
100/[1 + 2∆Ct(meth−unmeth) ]% [38]. Restriction-based methods, together with microarrays,
can also be used to provide localization information of DNA methylation [41]. The third
way is based on micro-array or sequencing [41]. For example, Edwards, et al., developed
a method called Methyl-MAPS (methylation mapping analysis by paired-end sequencing),
which combines MSREs (AciI, HhaI, HpaII, HpyCH4IV, and BstUI) and MDRE (McrBC)-
based restriction with deep sequencing, and could achieve single-CpG resolution and cover
up to 82.4% of all the CpG dinucleotides in the human and mouse genomes [42].
Methylated DNA immunoprecipitation (MeDIP): MeDIP is an efficient large-
scale technique that uses antibodies raised against methylated cytosines to enrich methy-
lated DNA fragments [43]. It consists of four steps. First, DNA is extracted, purified,
randomly sheared by sonication into fragments of 300-1,000 bps, denatured, and immuno-
precipitated with an antibody that detects 5-methylcytidine (5mC antibody) [44]. Secondly,
endopeptidase K is used to digest the antibodies and leave the methylated DNA intact.
Thirdly, phenol/chloroform is used to remove the digested proteins, and precipitation pu-
rifies the DNA [45]. Finally, the resulting purified methylated DNA fragments can then be
used for methylation studies by locus-specific PCRs [45], microarrays (MeDIP-chip) [46][47]
or sequencing (MeDIP-seq) [48].
Among these three techniques, bisulfite sequencing is the only one that provides single-
nucleotide resolution and covers the vast majority (>90%) of the genome. However, this
technique is more expensive than the other two, and suffers the drawback that the conversion
of unmethylated cytosines to uracils can be unstable [49]. Methylation specific restriction
enzyme digestion is generally simpler and faster to establish and requires no base modi-
fication. The disadvantage of this technique lies in that not all CpGs are located within
the recognition sites of the restriction enzymes, and that it gives rise to false-positives if
the enzyme digestion is not complete [50]. However, the recently emerged Methyl-MAPS,
which combines MSRE- and MDRE-based restriction with deep sequencing, could achieve
single CpG resolution and cover ≤ 82.4% of all the CpG dinucletoides in the human and
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mouse genomes. Although its coverage is a bit worse than the bisulfite sequencing tech-
niques, Methyl-MAPS is substantially cheaper and applicable to more repetitive regions,
and is therefore a very viable solution to the high resolution genome-wide DNA methylation
profiling [42]. The MeDIP methods have relatively lower resolution (a few hundred base
pairs at best), but less sequence bias than the other two techniques [24].
2.3 DNA Methylation Data Sets and Databases
2.3.1 Data sets
The Human Epigenome Project (HEP) was officially launched in 2003 by the Wellcome Trust
Sanger Institute, Epigenomics AG, and the Center National de Génotypage in Europe [51].
HEP aims to identify, catalogue and interpret genome-wide DNA methylation patterns of
all human genes in all major tissues [52]. Within this context, large scaled data sets have
been made available to archive the DNA methylation profiles in various tissues or cells.
DNA methylation profiling of the Human Major Histocompatibility Complex, the most
gene-dense region in the human genome containing genes with a diversity of functions on
chromosome 6 (6p21.3), was one of the first studies in HEP [53]. Eckhardt et al. later
created by far the most comprehensive and updated HEP data set by profiling 1.9 million
CpG dinucleotides of chromosomes 6, 20 and 22 of 43 samples from 12 different normal
human tissues [54].
Beyond HEP there are several other large-scaled data sets of DNA methylation, in-
cluding Lister, et al.’s [29] and Bell, et al.’s [55] that are based on bisulfite treatment,
methylation profiles of DNA (mPod) [48][47] and Weber, et al.’s [43][46] that are based on
MeDIP, as well as Methyl-MAPS [42], Kaminsky, et al.’s [56], Schumacher, et al.’s [57], and
Flanagan, et al.’s [58] that are based on methylation specific restriction enzyme digestion.
Lister, et al.’s data set is for human embryonic stem cell and fetal fibroblasts, and provides
the first genome-wide maps of methylated cytosines at the resolution of single nucleotides.
It covers ∼62 million and ∼45 million methylcytosines of all chromosomes in the embryonic
stem cell and fetal fibroblasts, respectively [29]. Bell, et al.’s data set is for lymphoblastoid
cell lines from 77 HapMap Yoruba individuals, and contains the methylation measurements
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of 22,290 CpG dinucleotides of all chromosomes [55]. mPod is based on a combination
of MeDIP, microarray and bioinformatic analysis, and contains the methylation status of
69,510 genomic regions (each ∼500 bps long) of 13 normal somatic tissues, placenta, sperm
and the GM06990 immortalized cell line [48][47]. Weber, et al., created two data sets, one
covering ∼6,000 CGIs of the primary fibroblasts, and the other covering ∼16,000 promoters
in primary somatic and germline cells [43][46]. Methyl-MAPS data set contains the methy-
lation status of 152,693,954 CpG dinucleotides for breast, and 75,676,854 CpG dinucleotides
in for brain [42]. Kaminsky, et al.’s data set contains the methylation status of 12,323 loci
in the white blood cells and buccal epithelial cells of monozygotic and dizygotic twins [56].
Schumacher, et al.’s data set contains the methylation status of CpG dinucleotides in chro-
mosomes 21 and 22 for prefontal cortex tissues of eight individuals, covering ∼ 0.1% of the
human genome [57]. Flanagan, et al.’s methylation data set covers ∼4,970 unique loci of
all chromosomes of the germ cell [58]. Schumacher et al.’s and Flanagan et al.’s data sets
are collected by MethyLogiX [59].
We summarize in Table 1 the cell, tissue or phenotypes of these data sets, as well as
their coverage, resolution, and underlying biochemical approaches. For other relevant but
non-human DNA methylation data sets (such as those for the mouse genome), the readers
are referred to [60, 28, 61] and the references therein.
2.3.2 Databases
In addition to the data sets, databases are being constructed to archive the DNA methy-
lation profiles and to link such information with other genotypic and phenotypic infor-
mation. Such databases include MethPrimerDB [62], MethDB [63], MethCancerDB [64],
PubMeth[65], MeInfoText[66], and MethyCancer [67].
MethPrimerDB (http://medgen.ugent.be/methprimerdb/) is a database of PCR primers
for DNA methylation profiling experiments [62]. So far, 259 primer sets contributed by 135
different resources that have been validated using PCR-based methylation assays are avail-
able.
MethDB (http://www.methdb.de/) aggregates and attempts to standardize the DNA
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Table 1: Summary of available major human genomic DNA methylation data sets and
their information
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methylation data from multiple resources. It currently contains over 19,905 methylation
content data and 5,382 methylation patterns or profiles for 48 species, 1,511 individuals,
198 tissues and cell lines, and 79 phenotypes [63]. Here, methylation content refers to
the percentage of methylated cytosines in the genome (without position information) [68];
methylation pattern refers to the methylation status of a series of CpG dinucleotides that
are located in close proximity and form a CpG-rich region [69]; methylation profile refers
to the methylation status of all cytosines in the genome [69]; and the phenotypes include
healthy, tumor, rheumatoid arthritis, etc.
MethCancerDB, PubMeth, MeInfoText, and MethyCancer are four major databases
containing cancer-related methylation information. MethCancerDB (http://www.methcancerdb.
net/methcancerdb/home.seam) contains the data collected from over 300 resources about
cancer-related aberrant CpG methylation. It focuses on the CGIs around genes (currently
covering 2,199 genes) and experimental designs such as diagnosis and prognosis [64]. Pub-
Meth (http://mit.lifescience.ntu.edu.tw/) is based on literature search, and contains
over 440 genes that are reported to be methylated in over 43 cancer types [65]. It con-
centrates on methylation frequency of genes in cancer samples without systematically dis-
tinguishing between cancer subphenotypes [70]. MeInfoText presents the profile of gene
methylation among over 205 human cancer types based on association mining from large
amounts of literature [66]. MethyCancer (http://methycancer.genomics.org.cn) inte-
grates data from public resources (e.g., MethDB and HEP) and from data produced from
China’s Cancer Epigenome Project. It currently contains over 485 annotated cancer genes
with methylation data from 511 cancer types [67]. We summarize in Table 2 the database
name, number of tissue/primer/cancer types, coverage, as well as their sources and refer-
ences.
2.4 Computational Modeling for DNA Methylation
A classical view is that CpG dinucleotides inside promoter-related CGIs are generally un-
methylated in normal tissues [71]. However, some pilot studies on methylation status of
CGIs show that a sizable fraction of CGIs are actually methylated in normal tissues [72][43].
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Table 2: Summary of existing major human genomic DNA methylation databases and
their main contribution
Database Name No. Tissue /Primer/Cancer
Type
Coverage Source Reference url
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It is still unclear what mechanisms determine certain CGIs to be methylated while others
not, and it has become more and more interesting to profile the methylation status of
CGIs in human genomes. In addition to biochemical experiment-based techniques for DNA
methylation profiling, computational prediction of DNA methylation has been carried out
by numerous researchers. Such computational predictions serve multiple purposes. First,
accurate predictions can contribute valuable information for speeding up genome-wide DNA
methylation profiling so that experimental resources can be focused on a selected few, while
computational procedures are applied to the bulk of the genome [6]. Second, computational
predictions can extract functional features and construct useful models of DNA methylation
based on existing data. These can be used as an initial step toward quantitative identi-
fication of critical factors or pathways controlling DNA methylation patterns [73]. Third,
computational prediction of DNA methylation can provide benchmark data to calibrate




The performance of a computational predictive model is commonly assessed by using three












TP + FN + TN + FP
, (3)
where TP, TN, FP and FN represent true-positives, true-negatives, false-positives, and
false-negatives, respectively. The definition of the positive and negative data are problem-
dependent [74].
2.4.2 Existing Models
Computational predictive models have been developed to identify CpG dinucleotides methy-
lated or unmethylated [75][76], CGIs (or CpG-rich segments) methylated or unmethylated
[74][6][77][78][79], and CGIs (or CpG-rich regions) that are differentially methylated in dif-
ferent tissues/cell types or phenotypes [9][80][81].
A key step for building computational predictive models is to select informative features.
For the prediction of DNA methylation, the features can be roughly grouped into two broad
categories: genetic and epigenetic. Given a region of interest (ROI), e.g., a CGI or a genomic
region centered around a particular CpG dinucleotide, the genetic features include:
1. general attributes of the ROI (e.g., length of the ROI, and distribution of the CpG
dinucleotides in the ROI);
2. patterns of the DNA composition of the ROI;
3. patterns of functional or conserved elements within or near the ROI;
4. structural and physicochemical properties of the ROI;
5. functions of the genes within or near the ROI;
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6. the extent of the diversity of the ROI within the population;
7. the extent of the conservation of the ROI among species;
The epigenetic features mainly regard the methylation and acetylation status of histones,
proteins serving as spools around which DNA winds and playing important roles in gene
regulation.
Bhasin, et al., used DNA composition features to predict the methylation of single
cytosines. A 39-nucleotide long DNA fragment centered around the cytosine of interest
was considered as the ROI, and each nucleotide in the ROI was coded by using a 5-bit
binary sparse code. In this way, each ROI was represented by a series of codes, and the
difference between ROIs was able to be quantified. An accuracy of about 75% was reported
using a support vector machine-based classifier [75]. Lu, et al., also used DNA composition
features for predicting whether a CpG dinucleotide is methylated or not. A 1,000 nucleotide
long DNA fragment centered around the CpG dinucleotide was used as the ROI, and the
frequencies of all pentamer oligonucleotides formed the features. An accuracy of about 77%
was reported for the CD4 lymphocytes data set using a nearest neighbor-based classifier
[76]. Feltus, et al., used frequencies of seven DNA patterns, TCCCCCNC, TTTCCTNC,
TCCNCCNCCC, GGAGNAAG, GAGANAAG, GCCACCCC, and GAGGAGGNNG, with
N representing any base, and achieved an accuracy of about 82% on the human fibroblast
data set when distinguishing between methylation-prone and methylation-resistant CGIs
using a linear programming-based classifier [9].
In addition to DNA composition features, Fang, et al., also used the distribution of the
repetitive element AluY, as well as the distribution of TFBSs, for predicting the methylation
status of CpG rich segments. They reported a specificity of about 84% and sensitivity of
about 84% on the human brain data set using a support vector machine-based classifier [74].
Bock, et al., used DNA composition features, predicted DNA helix structure, attributes of
repeat elements and TFBSs, evolutionary conservation of PhastCons elements [82] and the
number of single nucleotide polymorphisms (SNPs) for the prediction of CGI methylation
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[6][77], and their method achieved a high specificity (about 98%) but a relatively low sensi-
tivity (about 67%) on human lymphocytes using a support vector machine-based classifier
[79]. Ali, et al., also used the DNA composition information, predicted DNA structure,
and SNP features, and reported an accuracy of about 72% on the human lymphocytes
data set using a K nearest neighbor-based classifier [78]. To predict tissue-specific differen-
tially methylated regions (DMRs), Previti, et al., used CGI specific attributes, attributes
of repetitive elements, number and frequency of PhastCons elements, as well as structural
and physicochemical properties. When classifying CGIs into four categories: constitutively
methylated, constitutively unmethylated, tissue-specific DMR, and lack of methylation ex-
clusively in sperm, they reported an accuracy of about 89% using a decision tree-based
classifier [80]. Lv, et al., detected novel hypermethylated genes in breast cancer with area
under the receiver operating characteristic (ROC) curve (sensitivity vs. 1-specificity) larger
than 0.7 [81].
Computational prediction models that are solely based on genetic features can partially
characterize DNA methylation status. This is because DNA methylation, as an epigenetic
phenomenon, is affected by some other epigenetic factors, such as histone methylation and
histone acetylation. In light of the reported interaction between histone modification en-
zymes and DNA methylases [83][46], Fan, et al., found four histone methylation marks that
are highly correlated with the DNA methylation status of CGIs, and then incorporated these
histone methylation marks into the prediction of the methylation status of CGIs. Compared
to those methods without histone methylation information [79][77], the augmented features
indeed led to improved performance: a specificity of about 94% and a sensitivity of about
74% on the CD4 T cell data set using a support vector machine-based classifier [79].
2.4.3 Contribution
In this study, we analyze cancer-related aberrant DNA methylation, to identify patterns
indicative of methylation variation in normal versus cancerous cells. We identify those
CGIs that are methylated in human tumors, but are unmethylated in normal tissues. A
crucial step is to construct a high-resolution CGI methylation map genome-wide. Thus,
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we first investigate the association between the CGI methylation and various potentially
methylation-related feature classes. Our feature classes can be divided into eight categories:
1. CGI specific attributes;
2. DNA sequence patterns;
3. DNA structure patterns;
4. distribution of TFBSs;
5. distribution of the evolutionarily conserved elements;
6. gene functions;
7. histone methylation status;
8. histone acetylation status;
We select a subset of these features that show the most predictive power between methy-
lated and unmethylated CGIs by virtue of sequence analysis techniques and statistical tests,
and further build a binary classifier as well as a regression model with machine learning
techniques to construct the genome-wide map of the methylation status of CGIs. Finally,
we constructed novel models to detect those CGIs that are potentially to be subject to
aberrant methylation in different cancer types.
We identify 342 features that are statistically significantly associated with CGI methy-
lation in CD4 T cell. These features span across all the eight feature categories. We use
principal component analysis (PCA) to further decorrelate these features and build mod-
els for predicting binary CGI methylation status in normal CD4 T cell. Our models can
achieve an accuracy of about 93-94% , specificity of about 94% , and sensitivity of about
92-93%. We also demonstrate that our models can have high generalizability to other nor-
mal tissues and cell types as well. We also design regression models to profile the CGI
methylation in normal CD4 T cell instead of binary prediction. For cancer related aberrant
DNA methylation, we identify 88 features that are correlated with CGI differential methy-
lation in cancer. We also detect 75 and 45 discriminant features for aberrant methylation in
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colon and prostate cancer, respectively. Furthermore, based on these signature features, we
construct models that can achieve high accuracy (∼92%-∼93%), specificity (∼98%-∼99%)
as well as sensitivity (∼92%-∼93%) for predicting aberrantly methylated genes in both
the colon and prostate cancer, using housekeeping genes as a negative control group. We
also apply our computational models to all promoter CGIs in human genome to infer and
prioritize novel aberrantly methylated genes in cancer.
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CHAPTER III
OVERVIEW OF THE WORKFLOW
We aim to (1) develop computational predictive models to profile CGI methylation in normal
tissues and (2) to identify those CGIs that have high potential to be aberrantly methylated
in human cancers, but are unmethylated in normal tissues. We design the workflow for con-
structing such predictive models, as illustrated in Fig. 1. We first develop a computational
model using the HEP data set (which is based on the bisulfite sequencing technology and is
therefore of high resolution but low coverage) to provide the methylation status of all the
CGIs of the human genome. We then screen out those CGIs that are methylated in can-
cerous conditions (as indicated by MethCancerDB) but unmethylated in normal conditions
(according to the mPod data set and our computational predictions) to form the positive
data set; and screen out those CGIs of the housekeeping genes that are consistently un-
methylated (according to literature, the mPod data set and our computational predictions)
to form the negative data set. Finally, we build classifiers to detect the CGIs with high
potential of differential methylation patterns in cancerous conditions.
The CGI map for the study is obtained by applying the traditional Gardiner-Garden
sequence criteria on non-repetitive sequences of the human genome [84].
The core steps of our model development to analyze CGI methylation status and aber-
rant methylation potential of human genome consist of three parts - feature extraction,
feature selection and model construction through prediction tests.
For feature extraction, we use various resources to obtain or calculate both genetic
features (CGI specific attributes, DNA compositional attributes, structural attributes, gene
functional attributes, attributes related to evolutionary conservation, and attributes related
to transcription factor binding) and epigenetic features (histone methylation and histone
acetylation).
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Figure 1: Workflow used for the prediction of methylation status and cancer related
aberrant methylation of CGIs in human genome.
developed to identify features whose association with the methylation and aberrant methy-
lation of CGIs is statistically significant. We then use PCA to decorrelate the selected
features to further reduce dimensionality.
Finally, supervised learning based prediction tests are carried out to demonstrate to
what degree the CGI methylation status and aberrant methylation potential of the human
chromosomes can be identified using those principal components. The training and modified
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cross-validation in this study are performed using various data sets including HEP, mPod,
and MethCancerDB, and the assignment of aberrant methylation potential of CGIs are
based on the trained predictive models. These assignments are performed on all promoter
CGIs in the genome to prioritize potential novel aberrantly methylated genes. We give a




We prepare training data for constructing CGI methylation predictive models in normal
tissues, and the aberrant methylation predictive models in cancer, respectively. The tra-
ditional Gardiner-Garden criteria for CGI is adopted: (i) with ≥200 base pairs (bps), (ii)
with a GC content >50%, and (iii) with an observed/expected CpG ratio ≥60% [5]. Based
on these criteria, we obtain 27,639 CpG islands from the University of California, Santa
Cruz (UCSC) Human Genome Browser [85]. We incorporate various DNA methylation and
aberrant methylation resources including the HEP data set, mPod data set, MethCancerDB
database, and various databases such as Cancer Genes [86] for functional annotation of can-
cer related genes.
4.1 Training Data for Methylation Prediction in Normal Tissues
High-resolution methylation profiles of human chromosomes 6, 20, 22 are obtained from
the HEP data set [54]. The HEP data set provides a resource of about 1.9 million CpG
methylation values of 2,524 amplicons derived from 12 different tissues in 43 samples using
bisulfite DNA sequencing. The 12 different tissues consists of heart muscle, skeletal muscle,
liver, sperm, fetal skeletal muscle, fetal liver, placenta, melanocytes, dermal fibroblasts,
dermal keratinocytes, CD8 lymphocytes, and CD4 lymphocytes.
The HEP methylation intensity data of the CpG dinucleotides is calculated by comparing
the C to T peaks at CpG sites [53]. The methylation intensity value of the analyzed CpGs
ranges from 0 to 100 inclusive, where a value of zero corresponds to the lowest methylation
intensity and a value of 100 to the highest methylation intensity. The genomic coordinates
of the HEP data set are based on an old version of human genome assembly, and we map
the coordinates of these CpG dinucleotides to the human genome assembly NCBI36/hg18
using the UCSC Genome Browser liftOver tool [84]. We extract the CGIs more than 10%
of whose CpG dinucleotides are annotated with methylation intensities, and those CGIs
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constitute our training data set for constructing the model to predict CGI methylation. For
each tissue, the methylation intensity of a particular CpG dinucleotide was calculated as
the average of the same sites detected from different samples [87]. Then the methylation
intensity of a certain CGI is obtained by averaging over all the detected CpG dinucleotides
within it. CGIs with methylation intensity greater than 50 were regarded as the methylated
group, while less than 10 are treated as the unmethylated group [79].
Altogether, we have obtained 368 unmethylated CGIs and 101 methylated CGIs from
HEP CD4 lymphocytes for training our methylation predictive models. For generalizability
tests of the predictive models, we also extract the methylated and unmethylated CGIs in
other 11 tissue and cell types from the HEP data set. The distribution of CGIs of both
categories in each tissue or cell type is summarized in Table 3.
Table 3: Distribution of methylated and unmethylated CGIs among twelve different tissue
and cell types from chromosomes 6, 20, and 22 based on the CpG methylation data from
HEP.





heart muscle 96 372
skeletal muscle 91 371
fetal skeletal muscle 79 281
fetal liver 76 270
placenta 92 328
dermal melanocytes 107 326
dermal fibroblasts 92 358
dermal keratinocytes 91 374
4.2 Training Data for Cancer Related Aberrant Methylation Prediction
For cancer related aberrant methylation prediction, our training data set consists of cancer
related aberrant methylated CGIs (positive) and the CGIs that are consistently unmethy-
lated (negative). Figure 2 illustrates how we incorporate different information resources to
obtain the positive and negative groups.
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Figure 2: Quality control and functional annotation incorporating various resources for
cancer related aberrantly methylated CGIs (positive) and the CGIs that are consistently
unmethylated (negative).
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The positive data set is formed by integrating five databases, including MethCancerDB
[64], Cancer Gene Census (CGC) [88], Atlas of Genetics and Cytogenetics in Oncology
and Haematology (AGCOH) [89], Online Mendelian Inheritance in Man (OMIM) [90], and
Cancer Genes [86], that specify the (genetic vs. epigenetic) nature of cancer-related genes.
We only consider those genes that are original observations of aberrant methylation in cancer
from the MethCancerDB database, and extract the CGIs in their promoter regions. Since
the MethCancerDB database does not specify the functional type of aberrantly methylated
genes (e.g. oncogene or TSG), we further annotate the functional type of these genes by
the support from at least two of the popular cancer databases, including CGC, AGCOH,
OMIM, and Cancer Genes.
The negative data sets are formed by using the genes provided in [91] that are consis-
tently expressed at high levels across 42 different tissues and cell types. These genes are
named housekeeping genes and are believed to constitute a small set of genes required to
maintain minimum basic cellular function [91]. We treat these genes as the negative control
group based on the hypothesis that the promoter regions of the highly expressed genes are
generally unmethylated.
We observe, however, that so-generated data sets may contain errors. For example,
the gene KCNE4 (potassium voltage-gated channel, Isk-relate family, member 4) is with
aberrant methylation according to the MethCancerDB database, but has been reported in
[92] as methylated in normal tissues/cell types. To select the CGIs that are truly with
cancer related aberrant methylation and consistently unmethylated in normal tissues, we
used two more information resources, the mPod data set [47][48] and our computational
predictive model for methylation status built on the HEP data set (section 4.1) to provide
genome-wide prediction of the methylation status of CGIs in normal tissue/cell types, for
further processing [93].
We select mPod because of its high coverage of the genome that can complement the
HEP data set, and the diversity of tissue and cell types. The mPod data set contains
the genome-wide DNA methylation profiles from 16 normal tissues/cell types that were
obtained by using the MeDIP-chip technology accompanied with bioinformatics processing.
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It has a relatively high coverage (as shown in Table 4) that characterizes the methylation
status of 69,510 genomic fragments, but a relatively low resolution level in that each of
these genomic fragment is ∼500 bps long. In contrast, the HEP data set, which contains the
DNA methylation profiles of 12 normal tissues/cell types and is based on bisulfite sequencing
technology, has a relatively high resolution level that specifies the methylation status of CpG
dinucleotides but a relatively low coverage that only covers 1.9 million CpG dinucleotides
(corresponding to 553 CGIs with ≥10% of whose CpG dinucleotides are covered) of three
chromosomes (chr6, chr20, and chr22). To utilize both the mPod and HEP data sets to
check the methylation status of those potentially aberrantly methylated and consistently
unmethylated CGIs in the normal tissues and cell types, we first extend the coverage of the
HEP data set by developing a computational predictive model that used the HEP data set
for training and validation, and then use the mPod data set and this computational model
to select those CGIs that are consistently identified as unmethylated in normal tissues. It is
worthy of being pointed out that this extension and combination is meaningful because (i)
the computational predictive model is faithful to the HEP data set (accuracy of ∼93-94% ,
specificity of ∼94% , and sensitivity of ∼92-93%), and (ii) the mPod data set and predictions
from the computational model are not identical but highly correlated (correlation coefficient
= 0.84).
The coordinates of the genomic regions in the mPod data set are based on the human
genome assembly NCBI build 36/hg18. Each genomic region in this data set typically
contains 5×50-mer probes. For each genomic region, the methylation intensity in a certain
tissue is averaged over the methylation intensities of the probes within it [94]. Then the
methylation intensity of a certain CGI is calculated by averaging over all the 500 bp ROIs
overlapping with it.
Altogether, we identify 78 cancer related aberrantly methylated TSGs despite the cancer
type, 177 cancer related aberrantly methylated genes for colon cancer, and 122 cancer re-
lated aberrantly methylated genes for prostate cancer as the positive groups. We also select
a set of 783 housekeeping genes that are consistently unmethylated as the negative control
group. The genomic locations for the aberrantly methylated TSG genes are summarized in
25
Table 5, which includes the gene symbol, chromosome number, start and end position, as













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5: Genomic location for the 78 cancer related aberrantly methylated TSGs despite
the cancer type.
Gene Symbol Chromosome Number Start End Strand
AKR1B1 chr7 133777646 133794428 -
APAF1 chr12 97563208 97653342 +
APC chr5 112101454 112209835 +
APP chr21 26174731 26465003 -
BRCA2 chr13 31787616 31871809 +
C2orf40 chr2 106048544 106061041 +
CAMTA1 chr1 6767970 7752351 +
CASP8 chr2 201830998 201860679 +
CAV1 chr7 115952074 115988466 +
CD82 chr11 44543716 44597891 +
CDH1 chr16 67328695 67426945 +
CDH13 chr16 81218078 82387700 +
CDKN1B chr12 12761575 12766570 +
CDKN1C chr11 2861023 2863571 -
CFLAR chr2 201689060 201737248 +
CNTN4 chr3 2117246 3074645 +
CXCR4 chr2 136588388 136592195 -
CYP27B1 chr12 56442383 56447243 -
DKK1 chr10 53744046 53747423 +
DKK3 chr11 11941118 11986762 -
DLC1 chr8 12985242 13416766 -
DPP4 chr2 162557000 162639298 -
EFNA5 chr5 106744249 107034495 -
FABP3 chr1 31610686 31618510 -
FAS chr10 90740267 90765522 +
FHIT chr3 59710075 61212173 -
GJB2 chr13 19659604 19665114 -
GNMT chr6 43036477 43039596 +
GPX3 chr5 150380191 150388747 +
GSTP1 chr11 67107861 67110699 +
HIC1 chr17 1906353 1909731 +
IGFBP7 chr4 57592000 57671296 -
ING4 chr12 6629964 6642569 -
INTS6 chr13 50833701 50925276 -
IRF8 chr16 84490274 84513712 +
KL chr13 32488570 32538279 +
KLK10 chr19 56207811 56215243 -
LATS1 chr6 150023743 150081085 -
LOX chr5 121429917 121441853 -
MLH1 chr3 37009982 37067341 +
MSH2 chr2 47483766 47563864 +
MTHFR chr1 11768373 11788702 -
PGR chr11 100405564 100505754 -
POU2F3 chr11 119616160 119695863 +
PPP1R1B chr17 35036704 35046404 +
PRDM2 chr1 13903936 14024162 +
PRKCDBP chr11 6296751 6298316 -
PTEN chr10 89613174 89718512 +
PTGS2 chr1 184907591 184916179 -
PTPN13 chr4 87734908 87955326 +
PTPRG chr3 61522284 62254738 +
PTPRO chr12 15366753 15641602 +
RARB chr3 25444757 25614424 +
RASSF1 chr3 50342220 50353371 -
RASSF2 chr20 4708668 4743769 -
RASSF5 chr1 204747501 204829239 +
RB1 chr13 47775883 47954027 +
S100A2 chr1 151800208 151804930 -
SERPINB5 chr18 59295123 59323298 +
SFN chr1 27062219 27063534 +
SFRP1 chr8 41238634 41286137 -
SFRP5 chr10 99516497 99521746 -
SLIT2 chr4 19864332 20229886 +
SOCS1 chr16 11255774 11257540 -
SOCS3 chr17 73864456 73867753 -
SPRY2 chr13 79808112 79813087 -
STK11 chr19 1156797 1179434 +
TES chr7 115637816 115686073 +
TNFRSF10A chr8 23104914 23138584 -
TP53 chr17 7512444 7531588 -
TPM1 chr15 61121890 61151166 +
TSC22D1 chr13 43905654 44048701 -
UCHL1 chr4 40953685 40965203 +
VHL chr3 10158318 10168746 +
WIF1 chr12 63730672 63801383 -
WRN chr8 31010319 31150819 +
XAF1 chr17 6599879 6619688 +





As described in section 2.4.3, we investigate the association between CGI methylation and
eight categories of related feature classes. It is worth being pointed out that, among the
eight categories, we incorporate three sets of features that have not been extensively ex-
plored previously, including (i) the nucleosome positioning propensities of the CGI, (ii) the
acetylation status of nearby histones, and (iii) the functional roles of nearby genes. These
features add more dimensions of information as shown by PCA in section 6.1.1.
In the following paragraphs of A.1 to A.8., we describe how the features in these eight
categories are extracted.
A.1. The CGI specific attributes, including the GC content, length, and observed/expected
CpG ratio, are directly obtained from the UCSC human genome browser.
A.2. For the DNA compositional features, we focus on the frequencies of the tetramer
oligonucleotides and their z-scores; The z-score of a tetramer oligonucleotide fragment,





whereO(·) represents the observed frequency, E(·) and σ(·) represent the expected frequency
and standard deviation. E(N1N2N3N4) was estimated empirically based on a maximal-












A.3. For the DNA structural features, we focus on those basic characteristics capturing
the DNA 3-D conformation as well as the nucleosome positioning propensities. The DNA
conformation related attributes include twist, tilt, roll, shift, slide and rise, which are esti-
mated based on a model of dinucleotide stiffness [96]. For each of these six attributes, the
average value over all dinucleotides of the CGI is calculated.
Nucleosome positioning propensities of the CGIs are estimated based on the genome-
wide prediction of the nucleosome organization map [97]. There are two types of predictions,
one at the nucleotide level, and the other at the DNA fragment level. The nucleotide level
prediction regards the probability of each nucleotide being covered by any nucleosome,
which we calculate based on the mean and standard deviation over the entire CGI. The
fragment level prediction regards the nucleosome positioning potential of each 147 bp (the
typical length of a nucleosome) DNA fragment, which we calculate based on the mean and
standard deviation over all fragments overlapping with the CGI.
A.4. For the distribution of TFBSs, we download the data set for the locations and scores
of TFBS conserved in the human/mouse/rat alignment from the UCSC Genome Browser
[84]. A binding site can be considered to be conserved across the alignment if its score meets
the threshold score for its binding matrix in all 3 species [84]. Altogether, we obtain 115
TFBSs and map their genomic location to the CGIs. We then extract the features of the
occurrences and mean scores of each TFBS associated with each CGI. Furthermore, due to
the observed association of TFBS with CGI flanking regions [98], we extend both sides of
the CGIs up to 2,000 bp with a step size of 100 bp, and then recalculate the occurrences
and mean scores of each TFBS overlapping with the flanked CGIs.
A.5. We download the predictions of conserved elements from the UCSC Genome
Browser [84]. These predictions by the phastCons [82] provide evolutionarily conserved
elements across vertebrate, insect, worm, and yeast genomes. Each element is associated
with a log-odds score quantifying its degree of conservativeness across genomes. The score
is equal to its log probability under the conserved model minus its log probability under the
non-conserved model [84]. We retrieve the genomic coordinates for the conserved sites from
the table named phastConsElements17way, and then extract the number and mean scores
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of the evolutionary conserved elements overlapping with each CGI. To account for both the
short- and long-range association between these elements and CGIs, we consider flanking
regions of various lengths, ranging from 100 bps to 2,000 bps (with step size of 100 bps)
upstream and downstream of the CGI. We count the number of these elements overlapping
with the CGI, and calculated their average score.
A.6. We examine whether a CGI’s nearby genes are involved in any cancer-related
biological processes. A CGI’s nearby genes refer to those whose promoter region (from
the 1,000 bps upstream to the 200 bps downstream of the transcription start site) overlaps
with the CGI. A total of 37 biological processes (30 oncogene related, 11 tumor suppressor
related, and 4 common) are determined through gene ontology enrichment analysis of the
genes retrieved from the Cancer Gene Census [99]. A cancer-related biological process
was considered to be enriched if (i) the number of genes involved in the process is larger
than five, and (ii) the enrichment factor of the process is greater than one. If the gene
ontology annotations of a gene include one or more of these processes, the corresponding
gene function feature is assigned a value of 1, and 0 otherwise.
A.7. The histone methylation information is obtained from Barski, et al.’s data set,
which characterizes the genome wide distribution of 20 histone methylations, as well as
histone variants H2A.Z, RNA polymerase II, and the insulator binding protein CTCF in
CD4 lymphocytes [100]. Altogether we obtain about 186.9 million sequence tags, and the
number of tags detected for a particular position can be treated as proportional to the
histone methylation level of that position. We use the mean and standard deviation of the
number of tags over all nucleotides of a CGI to represent the methylation level of the CGI’s
nearby histones.
A.8. We obtain about 88.9 million sequence tags for 18 histone acetylations in CD4 lym-
phocytes from Wang, et al.’s data set [101]. These 18 histone acetylations are H2AK5ac,
H2AK9ac, H2BK5ac, H2BK12ac, H2BK20ac, H2BK120ac, H3K4ac, H3K9ac, H3K14ac,
H3K18ac, H3K23ac, H3K27ac, H3K36ac, H4K5ac, H4K8ac, H4K12ac, H4K16ac, and H4K91ac.
We then extract the genomic coordinates of these sequence tags, and map the obtained tags
of histone acetylation to the CGIs. We score the histone acetylation modification of each
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nucleotide position within the CGI by the number of tags covering that position. We then
calculate the mean and standard deviation of the histone acetylation intensities across all
the nucleotides within each CGI.
5.2 Feature Selection
The raw feature dimension is very high and the performance of supervised learning methods
would suffer from the curse of dimensionality. Aspects of the curse of dimensionality include
the need of large volume of training data to achieve high generalization accuracy, and the
time complexity of training the supervised learning methods [102]. As a result, selection of
subsets from the extracted large number of genomic and epigenetic features is important
for the predictive model construction. We thus carry out a two-stage selection procedure:
statistical test followed by PCA.
5.2.1 Statistical Test
There are three candidate statistical tests evaluated in this study to identify features whose
association with the methylation status of CGIs is statistically significant. The three sta-
tistical tests involved are as follows.
1) Fisher’s exact test [103], which is a statistical significance test to determine whether
there are nonrandom associations between two nominal variables. It is often used in the
analysis of contingency tables where sample sizes are small.
2) Chi-squared test [104], which is to determine if there is a significant difference between
the expected values and the observed values in one or more categories. Yates’ correction
[105] can be incorporated to improve the mathematical approximation for the test statistics.
3) Kolmogorov-Smirnov (KS) test [106], which compares the distributions of the values
in two samples to determine if they are from the same continuous distribution. The KS test
is distribution-free (i.e. makes no assumption about the distribution of data).
We implemented an algorithm to automatically select an appropriate statistical test for
the association analysis between the extracted features and the methylation status of CGIs.
The algorithm selects the optimal statistical test based on the following criteria. When the
feature variable is continuous, the algorithm selects the KS test. When the feature variable
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is categorical, the algorithm decide whether any of the expected values in the contingency
tables is extremely small (<5). If yes, the algorithm selects the Fisher’s exact test; otherwise,
the algorithm selects the Chi-squared test with Yates’ correction incorporated. The readers
are referred to [107][108] for the underlying mathematical principal for the statistical test
selection. For each of the tests, a feature is considered to be statistically significantly
associated with the methylation status of CGIs if the p-value yielded by the test is less than
0.05.
5.2.2 PCA
Besides their correlations with the CGI methylation or aberrant methylation, the identified
features might be inter-correlated. For example, the histone methylation and acetylation
status are likely to be correlated, because some acetylation and methylation (e.g. histone H3
at lysine 9) play opposite roles in gene activity [109]; DNA sequence and structure properties
are likely to be correlated, because most DNA structures are predicted based on DNA
sequences; and, the distribution of functional/evolutionarily conserved elements in a short
flanking neighborhood (e.g., +/- 200 bps) is likely to be correlated with the distribution
in a longer flanking neighborhood (e.g., +/- 2000 bps). The correlation between features
makes the feature space unnecessarily high-dimensional. To minimize the redundancy in
the features, we perform the PCA on those methylation-related features that are selected
via the above statistical tests. The PCA uses an orthogonal transformation to convert a set
of values of possibly correlated dimensions into a set of values of uncorrelated dimensions
called principal components [110]. Technically, given a collection of vectors in the original
feature space, {x} ⊂ X, the mean and covariance matrix of {x} are denoted as:
µx = E{x} (7)
Cx = E{(x− µx)(x− µx)T } (8)
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where E{·} represents the expected value. The components of Cx, denoted by cij , represents
the covariance between the ith and jth feature components. Via the singular value decom-
position [111] of the covariance matrix Cx, PCA derives a unitary matrix, Θ ∈ RM×M , to
map each x in the original M -dimensional feature space X to y ≡ [y1, y2, ..., yM ]T in a new
M -dimensional feature space Y ⊂ RM via the linear transformation
y = Θ(x− µx) (9)
Note that the order of new feature elements, y1, y2,..., yM , is related to the magnitude
of the projection of Cx onto the ith (i = 1, ...,M) axis in the new coordinate system [112].
That is, the first dimension (y1) corresponds to the projection with the largest magnitude,
the second (y2) corresponds to the projection with the second largest magnitude, etc. This
means that after PCA transformation, the feature components are completely decorrelated,
and the information contained in the original feature space before the transformation is
maximally retained in the first several number of components of the new feature space.
Therefore, by keeping only the first several components of the new feature space, most of
the information can still be retained while the redundancy in the feature collection is greatly
removed and the dimensionality of the feature space is greatly reduced. For PCA to work
properly, we subtract the mean from each of the feature dimensions.
5.3 Control Group
Housekeeping genes generally refer to constitutive genes that are necessary for the mainte-
nance of basic cellular function [113]. Since housekeeping genes constitutively expressed in
all tissues and their expression levels are comparatively constant across different cell types,
the corresponding CGIs are generally considered to be unmethylated [91]. To construct
the predictive model for the detection of the genes that are subject to aberrant methyla-
tion in cancer, we selected a set of 783 housekeeping genes as the negative control for the
cancer-related aberrant methylated genes [91]. These housekeeping genes are consistently
expressed as demonstrated by the gene expression profiles of 42 normal human tissues on
custom high density microarrays [91]. And, these housekeeping genes are further demon-
strated to be constitutively unmethylated across normal tissues as confirmed by the mPod
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data set and our computational predictive model built from HEP data set. Furthermore,
these housekeeping genes do not overlap with any of the aberrantly methylated genes in
colon and prostate cancers as shown by the MethCancerDB. We mapped the genomic coor-
dinates of these housekeeping genes to the NCBI36/hg18 assembly through UCSC Genome
Browser [114].
5.4 Prediction Test
We perform the support vector machine-based prediction test in three broad scenarios: DNA
methylation status binary classification, DNA methylation regression, and cancer-related
aberrant methylation detection. For DNA methylation status classification, we build com-
putational models to identify whether a CGI is methylated or unmethylated in normal
tissues; For DNA methylation regression, we predict the methylation level (continuous vari-
able) of each CGI; And for cancer-related aberrant methylation detection, we identify CGIs
that are potentially aberrantly methylated in cancer, including colon and prostate cancer.
In all scenarios, the inputs for the classifier construction are normalized between [0,1].
Since the accuracy of a support vector machine model is largely dependent on the selection
of the model parameters, we need to find the optimal parameter values in the (C,γ) space,
where C is the regularization parameter, and γ is the kernel parameter for the radial basis
function. We perform a two-stage grid search approach [115] in each fold of the cross-
validation experiment on the training data. In the first stage, we use a coarse grid with 10
search regions for each parameter. After identifying a better region on the grid, a finer grid
search on that region is conducted. The optimal values of (C,γ) pair are determined when
they yield the largest classification accuracy [116].
5.4.1 DNA Methylation Status Classification
The features selected through statistical tests and PCA are used to build support vector
machine-based models to predict the CGI methylation status. To examine the contribution
of the newly added features as well as the impact of the inhibitive-to-acquire histone mod-
ification information, we establish the following predictive models, (1) M1: a model with
all information being incorporated, (2) M2: a model with all but the histone modification
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information being incorporated, (3) M3–M9: seven models with individual or combinations
of the newly added features being excluded, and (4) M10–M16: seven models with individual
or combinations of the newly added features as well as the histone methylation information
being excluded. We use the CD4 lymphocyte data for training and validating the models,
while the data of the other 11 tissues/cell types for generalizability testing.
All these models are trained and validated by using a 10-fold cross validation scheme.
That is, all CGIs are partitioned randomly into 10 approximately equally-sized folds, each
of which is used in turn for validation while the remaining folds are used for training. The
performance of the classifiers is assessed by using three metrics defined in Eqns. (2)–(3),
namely, sensitivity (SE), specificity (SP), and accuracy (ACC). This partition-training-and-
validation procedure is repeated for 20 times, and the classifier performance is averaged over
the 200 validation folds. For fair comparisons with the existing method, a leave-one-out
cross-validation (LOOCV) scheme is also used. That is, each CGI is in turn used for
validation while the remaining CGIs are used for training. The performance of the model in
the LOOCV scheme is also assessed by the three metrics averaged over all validation CGIs.
Two predictive models built on the CD4 lymphocyte data are tested for generalizability
using the data of the other 11 tissues and cell types: one (M1) relying on all information,
while the other (M2) relying on all but the histone modification information. For the
former model, because the genome-wide histone methylation and acetylation profiles are not
available for these 11 tissues and cell types, we use the genome-wide histone modification
profiles in the CD4 lymphocytes, assuming that histone modifications in various cell types
are moderately or even highly correlated [117]. We also calculate the Pearson product
moment correlation coefficients of the CGI methylation levels across different tissues and
cell types to further support our computational results. Pearson product moment correlation







The value of r is such that −1 < r < +1. The + and − signs are used for positive linear
correlations and negative linear correlations, respectively.
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5.4.2 DNA Methylation Regression
To profile the specific methylation level of a CGI, we construct a regression model to predict
the profile of the methylation levels of the CGI using the CD4 lymphocyte data. Like
the binary classification model, the 10-fold cross validation scheme is implemented for the
training and validation, and is repeated 20 times. However, unlike the binary classification
model, a support vector regression model is designed to generate values ranging from 0 to
100, with 0 representing the lowest methylation intensity and 100 representing the highest
methylation intensity. The methylation intensity values are averaged over all the validations
and repeats to filter noise. We also perform the correlation analysis between the methylation
intensity generated by the regression models and the methylation value calculated by the
HEP data set.
5.4.3 Cancer-related Aberrant Methylation Prediction
The aberrant methylation of CGIs has been ascribed to the onset and progression of human
cancers [81][118]. We take advantage of the features selected through statistical tests and
PCA to construct support vector machine-based models to predict the CGIs that are subject
to aberrant methylation in cancer. Histone modification features are not used in such
prediction due to unavailability, and cancer-related gene function features are not used to
eliminate any prior knowledge. We select the training genes for aberrant methylation in
two different settings. In one setting, we select the aberrantly methylated TSGs, and in the
other we select aberrantly methylated genes in a specific cancer type. Besides the CGIs for
the aberrantly methylated genes, a set of 783 housekeeping genes are selected to serve as
the negative control group to make comparisons.
The number CGIs in the negative control group greatly outnumber the aberrantly
methylated genes in our training data. In this case, the traditional 10-fold cross valida-
tion has been found to be biased toward a group with the higher number of CGIs and
could yield misleading outcome [119]. To account for the imbalance of the training data, we
apply a modified 10-fold cross validation strategy to estimate the prediction accuracy. That
is, the CGIs of the housekeeping genes are first randomly partitioned into non-overlapping
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groups, with each group containing approximately the same number of CGIs as that of the
aberrantly methylated genes. Then, for each non-overlapping group and all the aberrantly
methylated genes, a stratified 10-fold cross validation is performed. That is, the aberrantly
methylated group and the non-overlapping control group are each randomly partitioned into
two portions. The portions with 10% of the CGIs from both groups are used for testing to
estimate the prediction accuracy, while the other portions with 90% of the CGIs are used
for building a support vector machine-based classifier. The above procedure is repeated for




6.1 Methylation Status Classification
6.1.1 Statistical Tests and PCA
Out of a total number of 841 features, 342 features were retained whose p-values in the
statistical tests were less than 0.05 [25, 93]. These features include two of the CGI spe-
cific attributes, 217 DNA compositional and eight DNA structural features, 35 functional
element features and two evolutionarily conserved element features, two features regarding
the functional roles of the neighboring genes, and 76 features related to the modification
status of nearby histones. Particularly, among the newly added features, two out of the
four nucleosome positioning features, all of the 36 histone acetylation features, and both
of the features regarding the functional roles of the neighboring genes were retained after
statistical tests.
Table 6: Number of principal components (PCs) required to retain a certain percentage
(Pcnt) of the total variance.
Pcnt 100% 99.99% 99.90% 99.00%
PCs 342 10 8 6
Pcnt 95.00% 90.00 75.0% 50.00%
PCs 5 4 3 2
PCA was performed to decorrelate these 342 selected features. Table 6 summarizes the
number of principal components that must be retained to keep a certain percentage of the
variance of the original feature space. Observe that the first eight principal components
together can account for the ∼99.90% of the variance in the original feature space and were
therefore used to build the predictive models. Fig. 3 depicts the contribution of each of the
342 original feature dimensions to the eight principal components.
Observe from Fig. 3 that each of the following eight categories of features, (i) the
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Figure 3: Contribution of the 342 features to the eight principal components. Each
column corresponds to a principal component, and each row corresponds to an original
feature dimension.
CGI specific attributes, (ii) DNA sequence patterns, (iii) DNA structure patterns, (iv)
distribution of TFBS, (v) distribution of the evolutionarily conserved elements, (vi) gene
functions, (vii) histone methylation and (viii) histone acetylation status, makes substantial
contributions to one or more principal components, suggesting that these categories of
information, though correlated, are complementary to a certain extent for predicting the
CGI methylation.
6.1.2 Performance of the Predictive Models on the CD4 Lymphocyte
The specificity, sensitivity, and accuracy measures of our predictive model M1 that incorpo-
rates all information are summarized in Table 7. Observe that both cross-validation schemes
rendered similar results, indicating that these measures can reliably characterize our model.
The performance of our classifier was compared to that of Fan et al.’s [79] method. Note
that both models incorporated the histone modification information and were evaluated
by using the HEP CD4 lymphocyte data to be fair. Observe that our model showed an
improved specificity and accuracy than Fan, et al.’s model while maintaining a comparable
sensitivity. Particular, our method achieved more than 20% boost in specificity in compar-
ison with Fan, et al.’s model. Furthermore, it was reported in [79] that when evaluated on
40
the human brain data, Fan, et. al.’s method could outperform another DNA methylation
prediction algorithm named Epigraph [77].
Table 7: Performance of our classifiers M1 on CD4 lymphocytes with comparison to the
existing method.
Method SP SE ACC
M1 (10-fold) 0.9405 0.9257 0.9313
M1 (LOOCV) 0.9429 0.9307 0.9403
Fan et al.’s [79] 0.7400 0.9428 0.8994
The improvement of model M1 over the existing model was partly due to the incorpora-
tion of the three new types of features – nucleosome positioning propensities, gene functions,
and histone acetylation status. The performance of our models M3 through M9, each with
an individual or a combination of the new types of features being excluded, are summarized
in Table 8. Observe that the performance of the predictive model deteriorated to differ-
ent extents when individual or combinations of the newly added features were excluded.
Specifically, the models without histone acetylation information (M3, M6, M7, and M9)
deteriorated more than those models with histone acetylation information but without the
other two types of newly added features (M4, M5, and M8). Therefore, histone acetylation
appears to be the most influential feature to the performance of the predictive model among
the newly added features.
We suspected that the information carried by the histone methylation features was too
dominant to fairly assess the influence of these newly added features; and therefore excluded
the histone methylation features and repeated the above experiments excluding individual
or combinations of the newly added features. The resultant models were M10 through
M16, and their performance was summarized in Table 8. Similarly, the models without an
individual or a combination of the newly added features deteriorated. It is noteworthy that
(1) the histone methylation and acetylation information greatly affected the sensitivity of
the models, and (2) the loss of histone methylation information could largely be made up by
including the histone acetylation information. This is not surprising, given that these two
forms of histone modifications are closely related as repeatedly observed in various tissues
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Table 8: Statistical measurements for the performance of the predictive models (M3
through M16), each with an individual or a combination of the newly added categories





All retained 0.9429 0.9405 0.9307 0.9257 0.9403 0.9313
Acetylation (M3) 0.9048 0.9012 0.9010 0.8965 0.9175 0.9046
Function roles (M4) 0.9319 0.9302 0.9315 0.9265 0.9362 0.9210
Nucleosome (M5) 0.9285 0.9270 0.9276 0.9250 0.9205 0.9205
Acetylation + Function roles (M6) 0.8876 0.8791 0.8912 0.8903 0.8915 0.8897
Acetylation + Nucleosome (M7) 0.8805 0.8698 0.8815 0.8835 0.8902 0.8826
Function roles + Nucleosome (M8) 0.9208 0.9186 0.9107 0.9116 0.9202 0.9186
All three (M9) 0.8775 0.8685 0.8810 0.8822 0.8806 0.8786
Histone Methyl Excluded
All but histone methylation 0.9321 0.9318 0.5941 0.5932 0.8593 0.8575
Acetylation (M10) 0.9701 0.9670 0.2277 0.2247 0.8102 0.8001
Function roles (M11) 0.9109 0.9092 0.5720 0.5670 0.8369 0.8312
Nucleosome (M12) 0.9088 0.9078 0.5682 0.5660 0.8298 0.8296
Acetylation + Function roles (M13) 0.9402 0.9320 0.2289 0.2279 0.7885 0.7862
Acetylation + Nucleosome (M14) 0.9381 0.9266 0.2302 0.2304 0.7752 0.7641
Function roles + Nucleosome (M15) 0.9012 0.8990 0.5520 0.5519 0.8252 0.8232
All three (M16) 0.9098 0.8972 0.2341 0.2338 0.7406 0.7352
and cell types [109].
6.1.3 Classifier Generalizability
The two predictive models, one with the histone modification information (M1) and the
other without (M2), that were both built on the human CD4 lymphocyte data were tested
on the data of the other 11 tissue and cell types for their generalizability. The sensitivity,
specificity, and accuracy of M1 and M2 during these testing experiments are summarized
in Table 9 and Table 10, respectively.
When the histone modification information was incorporated, the classifier model con-
structed on the CD4 lymphocyte data can be applied to most of the other tissues and cell
types (except for sperm) with little or no performance deterioration. When the histone
modification information was not incorporated, the performance of the predictive model on
the data of the other tissues and cell types deteriorated substantially, especially in terms
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of the sensitivity. However, if compared to the validation results where the histone modifi-
cation information was not used, the performance on the testing data was not unexpected.
Therefore, with or without the histone modification information, the predictive model es-
tablished on the CD4 lymphocyte data can well generalize to the other tissue or cell type
data.
Table 9: Generalizability performance of the methylation predictive model constructed
from the HEP CD4 lymphocytes data on 11 different tissues and cell types: with histone
modification.
Procedure Tissue/Cell Type SP SE ACC
Validation
CD4 (10-fold) 0.9405 0.9257 0.9313
CD4 (LOOCV) 0.9429 0.9307 0.9403
Testing
CD8 0.9608 0.8932 0.9448
liver 0.9680 0.8762 0.9465
heart muscle 0.9462 0.9479 0.9466
skeletal muscle 0.9542 0.9451 0.9524
embryonic skeletal 0.9395 0.9367 0.9389
embryonic liver 0.9259 0.9342 0.9277
placenta 0.9695 0.9130 0.9571
dermal melanocytes 0.9663 0.8785 0.9446
dermal fibroblasts 0.9525 0.9239 0.9467
dermal keratinocytes 0.9385 0.9341 0.9376
sperm 0.8459 0.9778 0.8617
Considering that DNA methylation is heavily involved in cellular differentiation, our
results in Tables 9 and 10 look suspicious. We therefore calculated the correlations of
the CGI methylation levels between different tissue and cell types, as depicted in Fig. 4.
Observe that the correlation coefficients between the somatic/placenta cells are very high
(mean: 0.9455, standard deviation: 0.0229), where the correlation coefficients between the
somatic/placenta and sperm cells are only moderate (mean: 0.6706, standard deviation:
0.0225). This suggests that the methylation status of CGIs are highly correlated in various
somatic/placenta cells, and therefore do not represent tissue-specific differentially methy-
lated regions. Our observations are consistent with recent studies [46][120] that there are
few variance in methylation levels of autosomal CGI promoters, and there is only a rela-
tively small fraction of CGIs with tissue-specific methylation. The difference between the
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Table 10: Generalizability performance of the methylation predictive model constructed
from the HEP CD4 lymphocytes data on 11 different tissues and cell types: without histone
modification.
Procedure Tissue/Cell Type SP SE ACC
Validation
CD4 (10-fold) 0.9670 0.2247 0.8001
CD4 (LOOCV) 0.9701 0.2277 0.8102
Testing
CD8 0.9722 0.2108 0.8104
liver 0.9678 0.2143 0.8122
heart muscle 0.9562 0.2386 0.8186
skeletal muscle 0.9594 0.2364 0.8306
embryonic skeletal 0.9425 0.2298 0.8100
embryonic liver 0.9389 0.2306 0.8054
placenta 0.9655 0.2184 0.8276
dermal melanocytes 0.9700 0.2186 0.8156
dermal fibroblasts 0.9605 0.2200 0.8237
dermal keratinocytes 0.9425 0.2204 0.8095
sperm 0.8524 0.2365 0.7625
somatic/placenta and sperm cells, as reflected by their moderate cross-correlations and the
performance deteriorations of our prediction models being applied to the sperm cell data,
suggests that gametes are epigenetically more deviated from somatic cells than somatic cells
themselves. This difference is likely related to the meiotic process, the special conditions
and gene expression required for gamete production [121].
6.2 Methylation Status Regression
We further performed support vector regression on the HEP data set to construct a regres-
sion model which can generate the methylation intensity of CGIs. The methylation intensi-
ties predicted by the regression model for the 368 unmethylated CGIs and 101 methylated
CGIs are illustrated in Fig. 5. The CGIs to the left of the red line are unmethylated from
the HEP data set, and to the right are methylated. To validate the prediction, we performed
Pearson correlation analysis of the predicted intensity with the intensity calculated from the
HEP data set. The correlation analysis demonstrated that the predicted intensity is highly
correlated with the intensity calculated from the HEP data set (correlation coefficient ρ =
0.883, p-value<4×10−122).
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Figure 4: Correlation coefficients of the CGI methylation levels across different tissues
and cell types.
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Figure 5: Methylation intensity generated by the regression analysis for the 368 unmethy-
lated CGIs and 101 methylated CGIs.
6.3 Aberrant Methylation Prediction
We first selected 78 CGIs that are differentially methylated and whose differential methy-
lation are related to some cancer types, and 783 CGIs that are constantly unmethylated
across various tissues, cells and phenotypes based on the data from MethCancerDB [64],
mPod [47][48], and our computational model [93]. Out of the 640 features regarding (1)
CGI specific attributes, (2) sequence composition of the CGI, (3) structure of the CGI, and
(4) distribution of TFBSs and conserved elements in or near the CGI, we obtained through
statistical tests 88 features having different distribution between differentially methylated
and constantly unmethylated CGIs. These 88 features include one CGI specific attribute,
35 DNA composition features, seven DNA structure features, 43 TFBS-related features, and
two evolutionarily conserved element-related features. Between the previous 342 features
that are statistically different between methylated and unmethylated CGIs and these 88
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features that are statistically different between differentially methylated and constantly un-
methylated CGIs, only 30 are in common. The first 33 principal components that can retain
99.99% variance in the original feature space were selected through PCA as shown in Table
11. Our results further demonstrated that the support vector machine-based classifier with
the reduced dimensional feature space rendered from PCA could achieve a ∼70% specificity,
∼73% sensitivity, and ∼71% accuracy in distinguishing the differentially methylated from
the constantly unmethylated CGIs.
Table 11: Number of genes, statistically significant features and PCs for different cases




# genes # features # PCs SP SE ACC
any cancer 78 88 33 0.70 0.73 0.71
colon 177 75 40 0.99 0.92 0.92
prostate 122 45 21 0.98 0.93 0.93
We then investigated 177 genes aberrantly methylated in colon cancer, treating the
housekeeping genes as the control. Through statistical tests, we identified 75 features
having different distribution between aberrantly methylated and constantly unmethylated
CGIs. These 75 features include one CGI specific attribute, 58 DNA composition features,
eight DNA structure features, six TFBS-related features, and two evolutionarily conserved
element-related features. By using the first 40 principal components that retains 99.99% of
the variance, our support vector machine-based classifier can reach ∼99% specificity, ∼92%
sensitivity, and ∼92% accuracy in distinguishing the aberrantly methylated in colon cancer
from the constantly unmethylated CGIs. Fig. 6 shows the histogram of the predicted scores
of all promoter CGIs using our computational predictive model for the potential of aberrant
methylation in colon cancer. As can be seen from Fig. 6, the predicted scores for the colon
cancer genes are concentrated in the lower range and the scores for the housekeeping genes
are concentrated in the higher range. Specifically, ∼83% of the colon cancer related genes
lie below the score 0.3, and ∼91% of the housekeeping gene CGIs lie above the score 0.7.
This prompts us to prioritize those CGIs with low predicted scores for further experimental
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validation as the aberrant methylation targets in colon cancer.
















Figure 6: Histogram of the predicted scores of all promoter CGIs for the potential of
aberrant methylation in colon cancer.
Likewise, for the 122 genes aberrantly methylated in prostate cancer, we identified 45
features showing statistical difference between aberrantly methylated and constantly un-
methylated CGIs. The identified features include two CGI specific attributes, 31 DNA
composition features, eight DNA structure features, two TFBS-related features, and two
evolutionarily conserved element-related features. By using the PCA-based model con-
structed from the first 21 principal components, we can achieve ∼98% specificity, ∼93%
sensitivity, and ∼93% accuracy in the classification. Similar observations can be made from
Fig. 7 for the prostate cancer as for the colon cancer. The predicted scores for the prostate
cancer genes and the housekeeping genes are concentrated in the two extreme ends. Specif-
ically, ∼85% of the prostate cancer related genes lie below the score 0.3, and ∼90% of the
housekeeping gene CGIs lie above the score 0.7. We can thus prioritize those CGIs with low
predicted scores for further biological experiment validation as the aberrant methylation
targets in prostate cancer.
Since some cancer-related aberrantly methylated genes are shared by these two cancer
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Figure 7: Histogram of the predicted scores of all promoter CGIs for the potential of
aberrant methylation in prostate cancer.
types, we further investigated the performance of our predictive models on the common
genes and non-common genes of the colon and prostate cancer. Table 12 summarized the
number of common and non-common genes between the two cancer types, as well as the
accuracy of the predictive models on all colon or prostate cancer related genes, the common
genes, and non-common genes. Observe from Table 12 that the model built from the colon
cancer genes can achieve better accuracy on the colon cancer genes than on the prostate
cancer genes. Particularly, an accuracy of ∼95% can be achieved for the colon cancer
specific genes while the accuracy drops to ∼71% on the prostate-cancer specific genes.
Similar observations can be made from the accuracy of the model constructed from the
the prostate cancer related genes. An accuracy of ∼93% can be achieved for the prostate
cancer specific genes while the accuracy drops to ∼75% on the colon cancer specific genes.
This indicates that our aberrantly methylation predictive model trained on a particular
cancer type is more specific to detect the aberrant methylation in that particular cancer
type, and the prediction accuracy would decrease when applying the model to a different
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cancer type. These observations suggest that different mechanisms exist in which DNA
methylation contributes to different cancer formation.
Table 12: Accuracy of the aberrant methylation predictive models on all colon or prostate
cancer related genes, the common genes shared by the two cancers types, and genes specific




all (177)specific (83)common (94)all (122)specific (28)common (94)
colon 0.9209 0.9518 0.8936 0.8525 0.7143 0.8936
prostate 0.8427 0.7470 0.9255 0.9262 0.9286 0.9255
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CHAPTER VII
CONCLUSION AND FUTURE WORK
7.1 Conclusion
DNA methylation is a type of epigenetic modification which involves the addition of a
methyl group to DNA via DNMT. The establishment of DNA methylation pattern is a
crucial part of cell differentiation and organ development, suppression of viral genes and
deleterious elements, and carcinogenesis. Computational predictions of DNA methylation
profiles serve multiple purposes. First, accurate predictions can contribute valuable in-
formation for speeding up genome-wide DNA methylation profiling so that experimental
resources can be focused on a few selected while computational procedures are applied to
the bulk of the genome. Second, computational predictions can extract functional features
and construct useful models of DNA methylation based on existing data, and can therefore
be used as an initial step toward quantitative identification of critical factors or pathways
controlling DNA methylation patterns. Third, computational prediction of DNA methyla-
tion can provide benchmark data to calibrate DNA methylation profiling equipment and to
consolidate profiling results from different techniques or equipments.
We studied the computational analysis of the DNA methylation patterns in human
genome. We incorporated multiple information resources, including (1) HEP and mPod that
specify DNA methylation information in normal tissues, (2) MethCancerDB that specify
aberrant methylation information in cancerous conditions, (3) CGC, AGCOH, CancerGenes
and OMIM for functional annotation, and (4) housekeeping genes from literature, for the
analysis. We designed and implemented various statistical tests, PCA, and model develop-
ment methods, and achieved predictive models with high performance.
We have identified various features that are associated with the methylation status of
the CGIs in human genome. We constructed support vector machine-based classifier models
to discriminate between CGIs that are prone to methylation from those that are resistant to
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methylation based on the identified features. In comparison with the existing methods, our
models can achieve higher performance with an accuracy of 93-94%, specificity of 94%, and
sensitivity of 92-93% for predicting CGI methylation status in normal CD4 lymphocytes
from the HEP data set. We showed that our models, constructed from CD4 lymphocytes,
can be applied to predict the methylation status of some other normal tissues and cell
types. To profile the methylation intensity of CGIs in normal tissues, we also built support
vector machine-based regression models, which generate continuous intensity values. We
showed that the intensity values generated by the regression models correlated well with
the intensities values based on the HEP data set (correlation coefficient ρ = 0.883, p-
value<4×10−122).
We also investigated patterns indicative of methylation variation in normal tissues versus
cancerous tissues. We performed the analysis of aberrant methylation under two different
settings: aberrant methylation in any type of cancer, and aberrant methylation in a spe-
cific cancer type. For the latter setting, we considered the colon and prostate cancer. We
correlated various features with cancer related aberrant methylation of CGI in these two
settings. More specifically, We identified 88 statistically significant features between aber-
rantly methylated and consistently unmethylated CGIs in cancerous conditions. We also
found 75 and 45 features showing differential patterns between aberrantly methylated and
consistently unmethylated CGIs for colon and prostate cancer, respectively. Furthermore,
based on these differential features, we built predictive models to detect such aberrantly
methylated CGIs in cancer via various modified cross-validation tests and generalization
tests. Experimental results showed that our predictive models can achieve high accuracy
(92-93%), specificity (98-99%) as well as sensitivity (92-93%) for both the colon and prostate
cancer. We also used our predictive models to all promoter CGIs in human genome to pri-
oritize potentially aberrantly methylated genes in cancer.
The major contribution of our study lies in three aspects. First, we detected various
genetic and epigenetic features that are associated with the methylation status and cancer
related aberrant methylation of the CGIs in human genome. Such features can serve as the
foundation for exploring the exact mechanisms of DNA methylation in normal organismal
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development and cancerogenesis. Second, our DNA methylation predictive model can serve
as a fast and effective way to explore genome-wide CGI methylation profiles in normal
tissues. Third, our predictive model for cancer related aberrant methylation can serve
as an initial step to prioritize and detect novel aberrantly methylated genes in cancerous
conditions.
7.2 Future Work
With the advance of experimental technologies for genome-wide DNA methylation profiling
and the expected bombardment of DNA methylation data, more challenges will be posed on
the subsequent computational epigenomics analysis to extract and abstract useful and con-
sistent information across these large amounts of data. Advanced techniques to effectively
process and integrate data of different resources and of different scales are in great need
to improve existing models or to establish novel models for DNA methylation and related
epigeneitc and genetic phenomena.
Though it is known that DNA methylation is heavily involved in the normal development
and differentiation, as well as in the onset and progression of diseases, the exact mechanisms
are yet to be discovered. It will certainly help to accelerate biomedical investigations if we
can, through computational predictions, comparative analyses, and evolutionary studies,
identify those DNA regions whose methylation variation patterns are correlated with, in-
dicative of, and underlying of the variations in gene expressions, histone modifications and
chromatin structures that are related to normal development, cell differentiation, genome
imprinting, X-chromosome inactivation, and phenotypic changes, respectively.
An improved understanding of the DNA methylation mechanisms, especially about the
DNA methylation variations with respect to other genetic or epigenetic modifications, will
help move towards a prospective DNA methylation-based pharmacology. Further challenges
may include modulating cancer growth and metastasis by targeting different proteins of
the DNA methylation machinery to achieve a balance of anticancer therapy with positive





The abbreviations used in this dissertation are summarized in Table 13.




CGC Cancer Gene Census
CGI CpG Island
CpG Cytosine-phosphate-Guanine




HEP Human Epigenome Project
LOOCV Leave-One-Out Cross-Validation
Methyl-MAPS Methylation Mapping Analysis by Paired-end Sequencing
MDRE Methylation Dependent Restriction Enzyme
MeDIP Methylated DNA Immunoprecipitation
mPod Methylation Profiles of DNA
MSRE Methylation Sensitive Restriction Enzyme
NCBI National Center for Biotechnology Information
OMIM Online Mendelian Inheritance in Man
PCA Principal Component Analysis
REBASE Restriction Enzyme Database
ROC Receiver Operating Characteristic




TFBS Transcription Factor Binding Site
TSG Tumor Suppressor Gene
UCSC University of California, Santa Cruz
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8.2 Enrichment Analysis
We examined whether a CGI’s nearby genes are involved in any cancer-related biological
processes. Altogether, we have identified 11 biological processes that are enriched by TSGs,
and 30 biological processes that are enriched by oncogenes. Four biological processes are en-
riched by both TSGs and oncogenes. These cancer-related biological processes are listed as
follows in Tables 14 and 15, with the four commonly enriched biological processes highlight
in italics.
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Table 14: Oncogene enriched biological processes with their GO identifiers and enrichment
factors.
Gene Ontology Name Enrich Factor
GO:0006355 regulation of transcription, DNA-dependent 1.8302
GO:0006350 transcription 1.8709
GO:0045449 regulation of transcription 2.411
GO:0007275 multicellular organismal development 1.3131
GO:0006468 protein amino acid phosphorylation 1.7815
GO:0006366 transcription from RNA polymerase II promoter 3.2426
GO:0007049 cell cycle 1.1148
GO:0007169 transmembrane receptor protein tyrosine kinase signaling 6.1067
GO:0008284 positive regulation of cell proliferation 2.7833
GO:0008283 cell proliferation 1.4073
GO:0030154 cell differentiation 1.0006
GO:0045944 + reg transcription from RNA polymerase II promoter 3.1473
GO:0006916 anti-apoptosis 2.3605
GO:0007166 cell surface receptor linked signaling pathway 1.7167
GO:0009887 organ morphogenesis 3.2937
GO:0045941 positive regulation of transcription 4.6435
GO:0001501 skeletal system development 2.6503
GO:0007242 intracellular signaling pathway 1.0491
GO:0042981 regulation of apoptosis 2.8612
GO:0051301 cell division 1.5936
GO:0000122 - reg transcription from RNA polymerase II promoter 2.1184
GO:0006461 protein complex assembly 1.8513
GO:0006897 endocytosis 2.2481
GO:0006974 response to DNA damage stimulus 1.2262
GO:0045893 positive regulation of transcription, DNA-dependent 2.8185
GO:0009653 anatomical structure morphogenesis 1.8513
GO:0016481 negative regulation of transcription 2.2164
GO:0016568 chromatin modification 1.3926
GO:0030097 hemopoiesis 5.6201
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB cascade 2.0437
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Table 15: TSG enriched biological processes with their GO identifiers and enrichment
factors.
Gene Ontology Name Enrich Factor
GO:0007049 cell cycle 5.1818
GO:0045786 negative regulation of cell cycle 17.8968
GO:0006281 DNA repair 8.9897
GO:0006974 response to DNA damage stimulus 9.9741
GO:0008285 negative regulation of cell proliferation 3.612
GO:0006289 nucleotide-excision repair 25.6002
GO:0006461 protein complex assembly 3.6879
GO:0007050 cell cycle arrest 6.5502
GO:0006298 mismatch repair 19.2483
GO:0006917 induction of apoptosis 3.4179
GO:0045944 + reg transcription from RNA polymerase II promoter 3.3247
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[44] F. Mohn, M. Weber, D. Schübeler, and T.C. Roloff. Methylated DNA immunopre-
cipitation (MeDIP). Angewandte Chemie, 50:6460C6468, 2011.
[45] K.L. Thu, E.A. Vucic, J.Y. Kennett, C. Heryet, C.J. Brown, W.L. Lam, and I.M.
Wilson. Methylated DNA immunoprecipitation. J Vis Exp., 23:935, 2009.
[46] M. Weber, I. Hellmann, M. Stadler, L. Ramos, S. Paabo, M. Rebhan, and
D. Schubeler. Distribution, silencing potential and evolutionary impact of promoter
DNA methylation in the human genome. Nature Genetics, 39:457–466, 2007.
[47] V.K. Rakyan, T.A. Down, N.P. Thorne, P. Flicek, E. Kulesha, S. Graf, E.M. Tomazou,
L. Backdahl, N. Johnson, M. Herberth, K.L. Howe, D.K. Jackson, M.M. Miretti,
H. Fiegler, J.C. Marioni, E. Birney, T.J.P. Hubbard, N.P. Carter, S. Tavare, and
S. Beck. An integrated resource for genome-wide identification and analysis of human
tissue-specific differentially methylated regions (tDMRs). GENOME RES, 18:1518–
1529, 2008.
[48] T.A. Down, V.K. Rakyan, D.J. Turner, P. Flicek, H. Li, E. Kulesha, S. Gräf, N. John-
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